Monika Joshi
A5029144224- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Cancer Immunotherapy and Biomarkers
- COVID-19 and healthcare impacts
- Renal cell carcinoma treatment
- Cancer Genomics and Diagnostics
- COVID-19 Clinical Research Studies
- Epigenetics and DNA Methylation
- Multiple and Secondary Primary Cancers
- Global Cancer Incidence and Screening
- Fibroblast Growth Factor Research
- Economic and Financial Impacts of Cancer
- Lung Cancer Treatments and Mutations
- Prostate Cancer Treatment and Research
- Renal and related cancers
- Colorectal Cancer Screening and Detection
- Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Cancer Research and Treatments
- Radiomics and Machine Learning in Medical Imaging
- Milk Quality and Mastitis in Dairy Cows
- Prostate Cancer Diagnosis and Treatment
- Cancer, Lipids, and Metabolism
- Cancer survivorship and care
- Ferroptosis and cancer prognosis
Penn State Milton S. Hershey Medical Center
2016-2025
Pennsylvania State University
2014-2024
Cancer Institute (WIA)
2015-2024
Rajasthan University of Veterinary and Animal Sciences
2020-2024
Cleveland Clinic
2021
Kerala Veterinary and Animal Sciences University
2020
Palmetto Hematology Oncology
2015
Hershey (United States)
2015
Government Medical College
2013
Harrisburg Hospital
2008-2010
Background Immune checkpoint inhibitors (ICIs) represent an appealing treatment for patients with advanced urothelial cancer (aUC) and a poor performance status (PS). However, the benefit of ICIs PS remains unknown. It was hypothesized that Eastern Cooperative Oncology Group (ECOG) (≥2 vs 0‐1) would correlate shorter overall survival (OS) in receiving ICIs. Methods In this retrospective cohort study, clinicopathologic, treatment, outcome data were collected aUC who treated at 18 institutions...
Breakthrough SARS-CoV-2 infections following vaccination against COVID-19 are of international concern. Patients with cancer have been observed to worse outcomes associated during the pandemic. We sought evaluate clinical characteristics and patients who developed breakthrough after 2 or 3 doses mRNA vaccines.
4503 Background: ERDA is an FGFR inhibitor with activity in pts mUC and FGFRalt. FGFRalt occur 10-20% of are enriched immunologically "cold" luminal 1 UC. Two independent published reports showed a 5% investigator-reported response rate to prior immune checkpoint inhibitors (ICI) among select FGFRalt, suggesting need for new treatment options this population. Here we report efficacy safety the global open-label phase 2 study BLC2001 (NCT02365597). Methods: Pts had measurable prespecified...
Recent success of using agents inhibiting the major immune check point, programmed cell death-1 (PD-1) pathway, offers a great promise for effective cancer therapy. Two blocking antibodies PD-1, nivolumab and pembrolizumab have recently been approved treating advanced recurrent non-small lung (NSCLC). Activation PD-1 on T cells PD-L1 tumor or antigen presenting leads to exhaustion ultimately growth. In this study, we performed flow cytometry analysis peripheral blood samples collected from...
Importance Cytokine storm due to COVID-19 can cause high morbidity and mortality may be more common in patients with cancer treated immunotherapy (IO) immune system activation. Objective To determine the association of baseline immunosuppression and/or IO-based therapies severity cytokine cancer. Design, Setting, Participants This registry-based retrospective cohort study included 12 046 reported Cancer Consortium (CCC19) registry from March 2020 May 2022. The CCC19 is a centralized...
Abstract Cancers arising from the bladder urothelium often exhibit lineage plasticity with regions of urothelial carcinoma adjacent to or admixed divergent histomorphology, most commonly squamous differentiation. To define biologic basis for and clinical significance this morphologic heterogeneity, here we perform integrated genomic analyses mixed histology cancers separable We find that differentiation is a marker intratumoral immunologic heterogeneity in patients cancer biomarker intrinsic...
Patients with bladder cancer (BC) who are cisplatin ineligible or have unresectable disease limited treatment options. Previously, we showed targeting programmed death-ligand 1 (PD-L1) durvalumab (durva) and radiation therapy (RT) combination was safe in BC. We now report results from a phase II study evaluating the toxicity efficacy of durva RT localized BC.This is single-arm, multi-institutional study; N=26. Enrolled patients had pure mixed urothelial BC (T2-4 N0-2 M0) tumors were unfit...
V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) mutated lung cancer is relatively aggressive and resistant to currently available therapies. In a recent phase II study for patients with BRAF-V600E non-small cell (NSCLC), BRAF V600E inhibitor demonstrated evidence of activity, but 30% this selected group progressed while on treatment, suggesting need developing alternative strategies. We tested two different options enhance the efficacy vemurafenib (BRAF inhibitor) in NSCLC. The first...
Urinary tract cancer can be pure urothelial carcinoma, nonurothelial carcinoma or variant (defined here as mixed carcinoma). Little is known regarding outcomes for patients with receiving immune checkpoint inhibitors. We hypothesized that does not compromise inhibitor efficacy in advanced carcinoma.We performed a retrospective cohort study across 18 institutions. Demographic, clinicopathological, treatment and data were collected who received Patients divided into vs subgroups, further by...
<h3>Importance</h3> Androgen deprivation therapy (ADT) has been theorized to decrease the severity of SARS-CoV-2 infection in patients with prostate cancer owing a potential tissue-based expression coreceptor transmembrane protease, serine 2 (TMPRSS2). <h3>Objective</h3> To examine whether ADT is associated decreased rate 30-day mortality from among cancer. <h3>Design, Setting, and Participants</h3> This cohort study analyzed patient data recorded COVID-19 Cancer Consortium registry between...
Abstract Epigenetic modulation is well established in hematologic malignancies but to a lesser degree solid tumors. Here we report the results of phase Ib/II study guadecitabine and durvalumab advanced clear cell renal carcinoma (ccRCC; NCT03308396). Patients received (starting at 60 mg/m 2 subcutaneously on days 1-5 with de-escalation 45 mg/m2 case dose limiting toxicity) (1500 mg intravenously day 8). The enrolled 57 patients, 6 Ib safety being primary objective 51in II, comprising...
We hypothesized that bevacizumab will potentiate activity of pembrolizumab. conducted a phase Ib/II, single-arm, multisite clinical trial the combination in metastatic renal cell carcinoma (RCC).
Objectives To compare clinical outcomes between patients with locally advanced (unresectable) or metastatic urothelial carcinoma (aUC) in the upper and lower urinary tract receiving immune checkpoint inhibitors (ICIs). Patients Methods We performed a retrospective cohort study collecting clinicopathological, treatment, outcome data for aUC ICIs from 2013 to 2020 across 24 institutions. compared objective response rate (ORR), overall survival (OS), progression‐free (PFS) UC (UTUC, LTUC). Uni‐...
Erdafitinib is indicated for the treatment of adults with locally advanced/metastatic urothelial carcinoma and susceptible FGFR3/2 alterations progressing on/after one or more lines prior platinum-based chemotherapy.To better understand frequency management select treatment-emergent adverse events (TEAEs) to enable optimal fibroblast growth factor receptor inhibitor (FGFRi) treatment.Longer-term efficacy safety results BLC2001 (NCT02365597) trial in patients advanced unresectable metastatic...
Background: The poultry production systems have led to marked increase in the of meat and eggs worldwide. use various phytobiotic feed additives as dietary supplements may positive effect on performance, carcass quality economic benefit birds. Methods: A feeding trial 42 days was conducted at Veterinary College, Navania, Udaipur year 2021 using 300, day-old broiler chicks (Cobb-400) randomly distributed completely randomized design. were divided into ten treatment groups with three...